PharmaDrug Appoints New Chairman Amid Strategic Corporate Shifts

LOS ANGELES- PharmaDrug Inc. a  specialty pharmaceutical firm dedicated to the advancement and commercialization of controlled substances and natural medicines, including psychedelics and previously sanctioned drugs, announced a significant leadership restructure. The company confirmed the appointment of Dr. David Kideckel as Chairman of the Board, succeeding Robert Steen, who will continue in his role as CEO.

This leadership transition underscores PharmaDrug’s strategic realignment as it embarks on critical phases of drug development and clinical trials. CEO Robert Steen expressed confidence in Dr. Kideckel’s capabilities, highlighting his extensive background in the pharmaceutical industry and his readiness to steer the company through upcoming clinical and manufacturing milestones.

Dr. Kideckel, the founder of Kideckel Advisory Group Inc., brings a wealth of experience to his new role, with nearly two decades spanning industry advisory, capital markets, and senior executive positions in notable healthcare and biotechnology firms. His academic credentials are equally impressive, holding a Doctorate in Neuroscience & Statistics and an MBA from the University of Toronto.

Under his leadership, PharmaDrug is poised for a transformational year, particularly with its focus on biosynthesis applications in pharmaceutical manufacturing and the development of PD-001, a potential multi-therapeutic agent for oncology and infectious diseases.

Sairiyo Therapeutics Update

PharmaDrug, through its majority ownership in Sairiyo Therapeutics Inc., has initiated a regulatory and clinical development plan in Australia to explore the efficacy of PD-001 in treating oncology and infectious diseases. This move is part of Sairiyo’s broader strategy to leverage Australia’s drug development incentives, including a significant tax rebate program.

SecureDose Progress

Simultaneously, SecureDose, another PharmaDrug initiative, is advancing towards the manufacturing phase after finalizing its drug formulation. The company is fine-tuning synthetic formulations to support the potential third wave of drug policy reform, with plans to announce specific target drugs and initiate test batch production in the near future.

PharmaDrug’s strategic advancements and leadership restructuring mark a pivotal moment in its mission to innovate within the pharmaceutical industry, focusing on the development of groundbreaking treatments and the efficient commercialization of controlled substances and natural medicines.